在FLT3突变的急性髓性白血病中,中素塑造了宏克隆和微克隆的演变
Romane Joudinaud1,2, Augustin Boudry2,3, Laurène Fenwarth1,2
1INSERM UMR1277, Centre National de la Recherche Scientifique UMR9020-CANTHER, Lille University Hospital, Université de Lille, Lille, France.
Blood advances
|October 17, 2024
概括
中素加密化疗 (ICT) 在复发性/耐药性急性髓性白血病 (AML) 中显示较低的FLT3-ITD持久性. 在诊断时多个FLT3-ITD克隆预测更高的持久性,即使在中氨酸治疗.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- FLT3突变性急性髓性白血病 (AML) 的前线治疗与中素 (MIDO) 和密集化疗 (ICT) 产生不完全缓解和高复发率.
- 了解FLT3突变AML中耐火/复发 (R/R) 疾病的分子机制对于改善结果至关重要.
研究的目的:
- 研究在患有FMS类激素激酶3 (FLT3) 突变急性髓性白血病 (AML) 的患者中驱动耐火/复发 (R/R) 疾病的分子机制.
- 分析FLT3克隆和转换在接受中素 (MIDO) 加重化疗 (ICT) 和单独ICT治疗的患者中的演变.
主要方法:
- 对150名R/R FLT3突变AML患者进行了回顾性多中心研究.
- 针对配对诊断-复发/耐药样本的高通量测序,以分析FLT3克隆和转换.
- 使用专门的算法来检测FLT3内部串联重复 (ITD) 微克隆 (AR <0.05) 和宏克隆 (AR ≥0.05).
主要成果:
- 与单独使用ICT (87.5%) 相比,在接受ICT+MIDO治疗的患者中,FLT3-ITD在R/R疾病中的持续性较低 (68%).
- 在接受ICT + MIDO治疗的患者中,在诊断时多个FLT3-ITD克隆与R/R疾病时更高的FLT3-ITD持久性 (88%) 有关.
- 在诊断时,很大一部分FLT3-ITD微克隆通过复发 (43%) 演变成宏克隆.
结论:
- 中素治疗与复发性/耐药性AML的FLT3-ITD克隆持续性降低有关.
- 在诊断时存在多个FLT3-ITD克隆是影响治疗耐药性和复发的关键参数.
- 这些发现突出了影响FLT3-ITD克隆在AML中的适应性和持续性的关键因素.
相关概念视频
Destabilization of Microtubules
2.6K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.6K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K


